151 related articles for article (PubMed ID: 12039995)
1. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30.
Süsal C; Pelzl S; Döhler B; Opelz G
J Am Soc Nephrol; 2002 Jun; 13(6):1650-6. PubMed ID: 12039995
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD30 as a predictor of kidney graft outcome.
Pelzl S; Opelz G; Wiesel M; Schnülle P; Schönemann C; Döhler B; Süsal C
Transplantation; 2002 Jan; 73(1):3-6. PubMed ID: 11792970
[TBL] [Abstract][Full Text] [Related]
3. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.
Süsal C; Pelzl S; Opelz G
Transplantation; 2003 Oct; 76(8):1231-2. PubMed ID: 14578759
[TBL] [Abstract][Full Text] [Related]
4. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations.
Matinlauri IH; Kyllönen LE; Salmela KT; Helin H; Pelzl S; Süsal C
Transplantation; 2005 Dec; 80(12):1809-12. PubMed ID: 16378078
[TBL] [Abstract][Full Text] [Related]
5. Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients' Survival.
Trailin AV; Ostapenko TI; Nykonenko TN; Nesterenko SN; Nykonenko OS
Dis Markers; 2017; 2017():9264904. PubMed ID: 28694560
[TBL] [Abstract][Full Text] [Related]
6. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
7. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
[TBL] [Abstract][Full Text] [Related]
8. Donor-specific antibodies require preactivated immune system to harm renal transplant.
Süsal C; Döhler B; Ruhenstroth A; Morath C; Slavcev A; Fehr T; Wagner E; Krüger B; Rees M; Balen S; Živčić-Ćosić S; Norman DJ; Kuypers D; Emonds MP; Pisarski P; Bösmüller C; Weimer R; Mytilineos J; Scherer S; Tran TH; Gombos P; Schemmer P; Zeier M; Opelz G;
EBioMedicine; 2016 Jul; 9():366-371. PubMed ID: 27333031
[TBL] [Abstract][Full Text] [Related]
9. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD30, Acute Rejection, and Graft Survival: Pre- and 6-Month Post-Transplant Determinations-When Is the Best Time to Measure?
de Holanda MI; Matuck T; de Carvalho DDBM; Domingues EMFL; Curvo R; Glasberg DS; Santos AMG; Borela ÁM; Pôrto LC
Transplant Proc; 2018 Apr; 50(3):728-736. PubMed ID: 29661425
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
Kim MS; Kim HJ; Kim SI; Ahn HJ; Ju MK; Kim HJ; Jeon KO; Kim YS
Transplantation; 2006 Dec; 82(12):1602-5. PubMed ID: 17198243
[TBL] [Abstract][Full Text] [Related]
12. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection.
Saini D; Ramachandran S; Nataraju A; Benshoff N; Liu W; Desai N; Chapman W; Mohanakumar T
Am J Transplant; 2008 Sep; 8(9):1798-808. PubMed ID: 18786226
[TBL] [Abstract][Full Text] [Related]
13. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
Vaidya S; Partlow D; Barnes T; Gugliuzza K
Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
[TBL] [Abstract][Full Text] [Related]
15. High serum level of the soluble CD30 identifies Chinese kidney transplant recipients at high risk of unfavorable outcome.
Iv R; He Q; Wang HP; Jin J; Chen Y; Chen JH
Transplant Proc; 2008 Dec; 40(10):3375-80. PubMed ID: 19100393
[TBL] [Abstract][Full Text] [Related]
16. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival.
Langan LL; Park LP; Hughes TL; Irish A; Luxton G; Witt CS; Christiansen FT
Am J Transplant; 2007 Apr; 7(4):847-56. PubMed ID: 17391128
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection.
Nafar M; Farrokhi F; Vaezi M; Entezari AE; Pour-Reza-Gholi F; Firoozan A; Eniollahi B
Int Urol Nephrol; 2009; 41(3):687-93. PubMed ID: 19142743
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection.
Cervelli C; Fontecchio G; Scimitarra M; Azzarone R; Famulari A; Pisani F; Battistoni C; Di Iulio B; Fracassi D; Scarnecchia MA; Papola F
Transplant Proc; 2009 May; 41(4):1159-61. PubMed ID: 19460505
[TBL] [Abstract][Full Text] [Related]
20. High soluble CD30 levels and associated anti-HLA antibodies in patients with failed renal allografts.
Karahan GE; Caliskan Y; Ozdilli K; Kekik C; Bakkaloglu H; Caliskan B; Turkmen A; Sever MS; Oguz FS
Int J Artif Organs; 2017 Jan; 39(11):547-552. PubMed ID: 28058698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
